A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: Efficacy on clinical signs and impact on the burden of illness

Dominique Bremond-Gignac, Riadh Messaoud, Sihem Lazreg, Claude Speeg-Schatz, Didier Renault, Frédéric Chiambaretta, A. Harrtani, T. Kaercher, M. Khairallah, B. Kocyla, B. Lorenz, B. Mortemousque, J. Murta, H. Nezzar, P. Nucci, J. Salgado-Borges, C. Tataru, M. Tatineanu, L. Voinea

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen. Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days. Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P

Original languageEnglish
Pages (from-to)725-732
Number of pages8
JournalClinical Ophthalmology
Volume9
DOIs
Publication statusPublished - Apr 20 2015

Fingerprint

Bacterial Conjunctivitis
Azithromycin
Cost of Illness
Ophthalmic Solutions
Tobramycin
Hyperemia
Controlled Clinical Trials
Signs and Symptoms
Therapeutics
Parents
Research Personnel

Keywords

  • Acceptability
  • Azithromycin
  • Bacterial conjunctivitis
  • Children
  • Compliance
  • QOL
  • Topical antibiotics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children : Efficacy on clinical signs and impact on the burden of illness. / Bremond-Gignac, Dominique; Messaoud, Riadh; Lazreg, Sihem; Speeg-Schatz, Claude; Renault, Didier; Chiambaretta, Frédéric; Harrtani, A.; Kaercher, T.; Khairallah, M.; Kocyla, B.; Lorenz, B.; Mortemousque, B.; Murta, J.; Nezzar, H.; Nucci, P.; Salgado-Borges, J.; Tataru, C.; Tatineanu, M.; Voinea, L.

In: Clinical Ophthalmology, Vol. 9, 20.04.2015, p. 725-732.

Research output: Contribution to journalArticle

Bremond-Gignac, D, Messaoud, R, Lazreg, S, Speeg-Schatz, C, Renault, D, Chiambaretta, F, Harrtani, A, Kaercher, T, Khairallah, M, Kocyla, B, Lorenz, B, Mortemousque, B, Murta, J, Nezzar, H, Nucci, P, Salgado-Borges, J, Tataru, C, Tatineanu, M & Voinea, L 2015, 'A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: Efficacy on clinical signs and impact on the burden of illness', Clinical Ophthalmology, vol. 9, pp. 725-732. https://doi.org/10.2147/OPTH.S78747
Bremond-Gignac, Dominique ; Messaoud, Riadh ; Lazreg, Sihem ; Speeg-Schatz, Claude ; Renault, Didier ; Chiambaretta, Frédéric ; Harrtani, A. ; Kaercher, T. ; Khairallah, M. ; Kocyla, B. ; Lorenz, B. ; Mortemousque, B. ; Murta, J. ; Nezzar, H. ; Nucci, P. ; Salgado-Borges, J. ; Tataru, C. ; Tatineanu, M. ; Voinea, L. / A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children : Efficacy on clinical signs and impact on the burden of illness. In: Clinical Ophthalmology. 2015 ; Vol. 9. pp. 725-732.
@article{c0849933dd124c64863d786a81df2778,
title = "A3-day regimen with azithromycin 1.5{\%} eyedrops for the treatment of purulent bacterial conjunctivitis in children: Efficacy on clinical signs and impact on the burden of illness",
abstract = "Purpose: To compare the efficacy of azithromycin 1.5{\%} versus tobramycin 0.3{\%} eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen. Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5{\%} was administered as 1 drop twice daily for 3 days, and tobramycin 0.3{\%} as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days. Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P",
keywords = "Acceptability, Azithromycin, Bacterial conjunctivitis, Children, Compliance, QOL, Topical antibiotics",
author = "Dominique Bremond-Gignac and Riadh Messaoud and Sihem Lazreg and Claude Speeg-Schatz and Didier Renault and Fr{\'e}d{\'e}ric Chiambaretta and A. Harrtani and T. Kaercher and M. Khairallah and B. Kocyla and B. Lorenz and B. Mortemousque and J. Murta and H. Nezzar and P. Nucci and J. Salgado-Borges and C. Tataru and M. Tatineanu and L. Voinea",
year = "2015",
month = "4",
day = "20",
doi = "10.2147/OPTH.S78747",
language = "English",
volume = "9",
pages = "725--732",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children

T2 - Efficacy on clinical signs and impact on the burden of illness

AU - Bremond-Gignac, Dominique

AU - Messaoud, Riadh

AU - Lazreg, Sihem

AU - Speeg-Schatz, Claude

AU - Renault, Didier

AU - Chiambaretta, Frédéric

AU - Harrtani, A.

AU - Kaercher, T.

AU - Khairallah, M.

AU - Kocyla, B.

AU - Lorenz, B.

AU - Mortemousque, B.

AU - Murta, J.

AU - Nezzar, H.

AU - Nucci, P.

AU - Salgado-Borges, J.

AU - Tataru, C.

AU - Tatineanu, M.

AU - Voinea, L.

PY - 2015/4/20

Y1 - 2015/4/20

N2 - Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen. Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days. Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P

AB - Purpose: To compare the efficacy of azithromycin 1.5% versus tobramycin 0.3% eyedrops on clinical ocular signs and symptoms of bacterial conjunctivitis in children and to assess the parents’ satisfaction regarding the dosing regimen. Patients and methods: An international, multicenter, randomized, investigator-masked, controlled clinical trial conducted in children (1 day to 18 years old) with bulbar conjunctival hyperemia and purulent discharge. Azithromycin 1.5% was administered as 1 drop twice daily for 3 days, and tobramycin 0.3% as 1 drop every 2 hours for 2 days, then 4 times daily for 5 days. Results: A total of 286 patients (mean age: 3.2 years) were enrolled. In children with bacteriologically positive cultures (N=203), azithromycin produced a significantly greater improvement in conjunctival discharge (P

KW - Acceptability

KW - Azithromycin

KW - Bacterial conjunctivitis

KW - Children

KW - Compliance

KW - QOL

KW - Topical antibiotics

UR - http://www.scopus.com/inward/record.url?scp=84929574680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929574680&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S78747

DO - 10.2147/OPTH.S78747

M3 - Article

AN - SCOPUS:84929574680

VL - 9

SP - 725

EP - 732

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -